Jan 16 (Reuters) - Eyenovia Inc EYEN.O :
* EYENOVIA RE-ACQUIRES DEVELOPMENT AND COMMERCIALIZATION
RIGHTS TO
MICROPINE IN THE U.S. AND CANADA
* EYENOVIA- BY DEAL, CO TO PAY BAUSCH + LOMB IRELAND LIMITED
AN
UPFRONT PAYMENT CONSISTING OF $2 MILLION IN CASH AND $3 MILLION
IN SHARES OF COMMON STOCK
* EYENOVIA : TO ACCELERATE ONGOING CHAPERONE PHASE III
TRIAL,
ENGAGE WITH FDA TO EXPLORE OPTIONS TO EXPEDITE DEVELOPMENT,
REGISTRATION OF MICROPINE
* EYENOVIA: TO PAY BAUSCH + LOMB IRELAND LIMITED UPFRONT
PAYMENT
CONSISTING OF $2 MILLION IN CASH, $3 MILLION IN SHARES
* EYENOVIA: TO PAY BAUSCH + LOMB IRELAND LIMITED LOW
SINGLE-DIGIT
ROYALTY ON EYENOVIA'S NET SALES OF MICROPINE IN UNITED STATES
AND CANADA
* EYENOVIA INC - AGREEMENT HAS NO IMPACT ON EYENOVIA'S
ONGOING
PARTNERSHIP WITH ARCTIC VISION
Source text for Eikon: ID:nGNX6S5q7b
Further company coverage: EYEN.O
((Reuters.Briefs@thomsonreuters.com;))